Global Cord Blood Corp. Looks Anemic on Slow Growth, Regulatory Concerns
Leading cord blood company’s stock briefly surged in February on positive industry news, but has been generally sluggish despite its dominant position in China Key Takeaways: Global Cord Blood Corp.’s…
RELATED ARTICLES
-
Yibin Bank’s IPO spotlights challenges facing regional lenders
2596.HK -
Youdao looks to parent, global markets to revive stalling growth
DAO.US
-
Seyond may get stuck in slow-moving SPAC lane to Hong Kong listing
7855.HK
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
- Mao Geping’s Hong Kong IPO gets lift from regulatory nod
-
FinVolution finds riches, achieves growth despite headwinds, in global markets
FINV.US
